Is Eone Diagnomics Genome Center (KOSDAQ:245620) Weighed On By Its Debt Load?
Apr 06
South Korean (KOSPI) Clinical Research and Equipment Industry Analysis
UpdatedJan 31, 2023
DataAggregated Company Financials
Companies33
- 7D0.5%
- 3M-8.3%
- 1Y5.0%
- YTD-3.0%
The Clinical Research and Equipment industry is up 1.2% in the last week, with Samsung BiologicsLtd up 0.4%. In the last 12 months, the industry was up 5.7%. Earnings are forecast to grow by 19% annually.
Industry Valuation and Performance
Has the South Korean Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 31 Jan 2023 | ₩62.6t | ₩3.5t | ₩426.6b | 20.2x | 146.9x | 18x |
| Thu, 29 Dec 2022 | ₩64.8t | ₩3.4t | ₩428.7b | 20.6x | 151.2x | 18.9x |
| Sat, 26 Nov 2022 | ₩69.8t | ₩3.4t | ₩445.5b | 21.9x | 156.6x | 20.5x |
| Mon, 24 Oct 2022 | ₩65.6t | ₩3.0t | ₩448.5b | 23.1x | 146.2x | 22x |
| Wed, 21 Sep 2022 | ₩62.7t | ₩3.0t | ₩448.5b | 26.4x | 139.9x | 21x |
| Fri, 19 Aug 2022 | ₩69.0t | ₩2.7t | ₩454.7b | 29.5x | 151.9x | 25.4x |
| Sun, 17 Jul 2022 | ₩64.9t | ₩2.7t | ₩454.7b | 28.7x | 142.8x | 23.9x |
| Tue, 14 Jun 2022 | ₩63.6t | ₩2.7t | ₩454.7b | 25.3x | 139.8x | 23.4x |
| Thu, 12 May 2022 | ₩62.9t | ₩2.4t | ₩379.4b | 22.7x | 165.7x | 25.9x |
| Sat, 09 Apr 2022 | ₩60.2t | ₩2.4t | ₩379.4b | 25x | 158.8x | 24.8x |
| Mon, 07 Mar 2022 | ₩57.8t | ₩2.4t | ₩408.2b | 26x | 141.7x | 24.6x |
| Wed, 02 Feb 2022 | ₩55.6t | ₩2.3t | ₩412.7b | 23.7x | 134.7x | 23.7x |
| Fri, 31 Dec 2021 | ₩67.8t | ₩2.3t | ₩412.7b | 28.3x | 164.4x | 28.9x |
| Sun, 28 Nov 2021 | ₩64.9t | ₩2.3t | ₩390.6b | 26.2x | 166x | 28x |
| Tue, 26 Oct 2021 | ₩64.9t | ₩2.1t | ₩329.9b | 27.1x | 196.8x | 30.2x |
| Thu, 23 Sep 2021 | ₩69.7t | ₩2.1t | ₩329.9b | 31.2x | 211.2x | 32.4x |
| Sat, 21 Aug 2021 | ₩73.0t | ₩2.2t | ₩336.8b | 32.9x | 216.7x | 33x |
| Sat, 05 Jun 2021 | ₩64.3t | ₩2.1t | ₩247.5b | 38.6x | 259.8x | 30.9x |
| Tue, 09 Mar 2021 | ₩57.5t | ₩2.0t | ₩213.0b | 64.8x | 269.9x | 29x |
| Mon, 30 Nov 2020 | ₩59.9t | ₩1.8t | ₩306.1b | 59.1x | 195.6x | 32.4x |
| Thu, 03 Sep 2020 | ₩59.4t | ₩1.7t | ₩273.1b | 77.8x | 217.6x | 36x |
| Sun, 07 Jun 2020 | ₩45.7t | ₩1.4t | ₩209.9b | 76.6x | 217.7x | 32.8x |
| Sat, 29 Feb 2020 | ₩34.0t | ₩1.2t | ₩177.8b | 57x | 191.1x | 28x |
Price to Earnings Ratio
198.1x
Current Industry PE
- Investors are pessimistic on the South Korean Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 148x which is lower than its 3-year average PE of 189x.
- The 3-year average PS ratio of 27.8x is higher than the industry's current PS ratio of 18.1x.
Past Earnings Growth
- The earnings for companies in the Life Sciences Tools and Services industry have grown 34% per year over the last three years.
- Revenues for these companies have grown 42% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Comparison
How does South Korean Clinical Research and Equipment compare with similar industries?
| KR Market | 2.46% | |
| Healthcare | 0.63% | |
| Life Sciences | 0.46% | |
| Clinical Research and Equipment | 0.46% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| A268600 Cellivery Therapeutics | ₩13.06k | 37.0% +₩128.4b | -18.2% | PS22.3x | |
| A087010 Peptron | ₩8.32k | 9.5% +₩14.9b | -6.0% | PS29.5x | |
| A220100 FutureChemLtd | ₩9.80k | 5.0% +₩10.4b | -20.4% | PS18.5x | |
| A038290 Macrogen | ₩21.50k | 4.9% +₩8.3b | -12.2% | PE95.6x | |
| A245620 Eone Diagnomics Genome Center | ₩1.87k | 3.9% +₩5.9b | -56.0% | PS1.7x |